GLP‐1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta‐analysis including the REWIND and PIONEER 6 trials

Data from 56,004 patients indicate that glucagon-like peptide-1 receptor agonists reduce major cardiovascular events by 13%.

• Glucagon-like peptide-1 receptor agonists are associated with a 12% reduction in cardiovascular death.
• The risk of non-fatal stroke decreases by 16% with glucagon-like peptide-1 receptor agonist treatment.
• Hospitalization for heart failure is reduced by 9% in patients receiving glucagon-like peptide-1 receptor agonists.
• All-cause mortality is lowered by 11% among those treated with glucagon-like peptide-1 receptor agonists.
• A 17% reduction in a broad composite kidney outcome is observed, primarily due to decreased macroalbuminuria.

AI simplified